ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
4.6.2026 08:30:00 CEST | GlobeNewswire by notified | Press release
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.
At two ALK symposia, FlashTalk, oral and poster sessions at the EAACI 2026 scientific programme, ALK will present data on real-world use and clinical implementation of nasal adrenaline in anaphylaxis and share key learnings from 20 years of experience with SLIT tablets.
The two symposia will take place as follows:
Friday 12 June, 12:00-13:00:
From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis.
The symposium will address the unmet needs in paediatric and adult anaphylaxis management, the role of nasal adrenaline, including a presentation of real-world use, patient preference and clinical implementation.
Saturday 13 June, 12:00-13:00:
20 years of SQ SLIT-tablet experience: Key learnings and new horizons
The symposium will address the disease modifying and preventative benefits of allergy immunotherapy, the clinical benefits beyond allergic rhinitis and share efficacy and safety outcomes of a peanut SLIT-tablet phase I/II trial.
Simon Lawton, Global Medical Affairs, Chief medical Office at ALK says:
“We are looking forward to contributing to this year’s EAACI congress where we will showcase the important innovation under way at ALK across anaphylaxis and food allergy. We will also share key insights grounded in robust science and 20 years’ experience with SLIT-tablets. We hope that many EAACI attendees will join our symposia.”
In total, ALK has contributed to 29 abstracts in the scientific programme. Of particular note are additional efficacy and safety findings from clinical trials in adults and children with allergic rhinitis/rhino conjunctivitis treated with SLIT-tablets.
Key highlights of ALK’s contribution include:
| Therapy area | Abstract title | Lead author | Abstract Number/ Presentation Details |
| Anaphylaxis | Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment | Worm M | #001368 Thematic poster session Sunday 14 June 2026, 12:15-13:15 |
| Anaphylaxis | Healthcare Professionals’ Perspectives on Anaphylaxis Management: A Multi-Country Survey comparing Adrenaline Auto-Injectors and Nasal Adrenaline Sprays | Fox A | #001283 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Anaphylaxis | Intranasal Adrenaline Associated with Lower Administration-Related Anxiety and Higher Willingness to Use Versus Adrenaline Auto-Injectors | Mack D | #000889 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Anaphylaxis | Comparative Ease-of-Use Assessment of a Nasal Adrenaline Spray with an Adrenaline Auto-Injector in Children, Adults and Caregivers | Mack D | #000890 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Respiratory allergy | Effect of SQ SLIT-tablets on asthma symptoms and safety in children with allergic rhinitis and with or without concomitant asthma across multiple trials | Pfaar O | #000781 Oral presentation Sunday 14 June 2026, 08:45 - 10:15 |
| Respiratory allergy | Symptom control and reduced intranasal corticosteroid use in children with allergic rhinitis/rhinoconjunctivitis treated with SQ house dust mite SLIT-tablet: A responder analysis | Pfaar O | #000815 Flash talks session Sunday 14 June 2026, 12:15-13:15 |
| Respiratory allergy | Reduction in symptom and medication scores in the first week of the first pollen season in children and adults treated with SQ SLIT-tablets across phase III trials | Durham S | #100185 Flash talks session Sunday 14th June 2026, 12:15 – 13:15 |
| Real-world evidence | Long-term real-world effectiveness of allergen immunotherapy on respiratory infections in children and adults with allergic rhinitis and asthma | Woehlk C | #000748 Flash talks session Friday 12 June 2026, 12:00-13:00 |
| Real-world evidence | Effectiveness of sublingual immunotherapy (SLIT) tablets on dispensed asthma medications and treatment regimens: Results from the Real-world Evidence of aLlergy immunotherapY (RELY) study | Woehlk C | #000751 Oral presentation Saturday 13 June 2026, 13:15-14:45 |
| Real-world evidence | Long-term effectiveness of HDM SLIT-tablets on symptom-relieving prescriptions: Results from the Japanese register-based study, Real-world Evidence of house dust Mite sublingual Immunotherapy Tablets (REMIT) | Durham S | #001258 Oral presentation Saturday 13 June 2026, 13:15-14:45 |
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin